Costs of traditional Chinese medicine treatment for inpatients with lung cancer in China: a national study

Abstract

Background Traditional Chinese Medicine (TCM) has long been a widely recognized medical approach and has been covered by China’s basic medical insurance schemes to treat lung cancer. But there was a lack of nationwide research to illustrate the impact of the use of TCM on lung cancer patients’ economic burden in mainland China. Therefore, we conduct a nationwide study to reveal whether the use of TCM could increase or decrease the medical expenditure of lung cancer inpatients in mainland China. Methods This is a 7-year cross-sectional study from 2010 to 2016. The data is a random sample of 5% from lung cancer claims data records of Chinese Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident Basic Medical Insurance (URBMI). Mann-Whitney test was used to compare inpatient cost data with positive skewness. Ordinary least squares regression analysis was performed to compare the total TCM users’ hospitalization cost with TCM nonusers’, to examine whether TCM use is the key factor inducing relatively high medical expenditure. Result A total of 47,393 lung cancer inpatients were included in this study, with 38,697 (81.7%) of them at least using one kind of TCM approach. The per inpatient medical cost of TCM users was RMB18,798 (USD2,830), which was 65.2% significantly higher than that of TCM nonusers (P < 0.001). The medication cost, conventional medication cost, and nonpharmacy cost of TCM users were all higher than TCM nonusers, illustrating the higher medical cost of TCM users was not induced by TCM only. With confounding factors fixed, there was a positive correlation between TCM cost and conventional medication cost, nonpharmacy cost (Coef. = 0.283 and 0.211, all P < 0.001), indicting synchronous increase of TCM costs and conventional medication cost for TCM users. Conclusion The use of TCM could not offset the utilization of conventional medicine, demonstrating TCM mainly played a complementary role but not an alternative role in the inpatient treatment of lung cancer. A joint Clinical Guideline that could balance the use of TCM and Conventional medicine should be developed for the purpose of reducing economic burden for lung cancer inpatients.

The survival and cost-effectiveness analysis of adjunctive Chinese medicine therapy for patients with non-small cell lung cancer: a nationwide cohort study in Taiwan

“…There is some relevant literature, such as a study from mainland China in 2023 that reported on medical expenses for lung cancer inpatients. Between 2010 and 2016, there were a total of 47,393 lung cancer inpatients, and the median annual total medical expenses (Western medicine + Chinese medicine) per patient for those receiving Chinese medicine therapy were 18,798 RMB (approximately NT$ 82,711) (Nie et al, 2023). This study included a total of 43,122 NSCLC patients from 2007 to 2018.…”

A mast cell-related prognostic model for non-small cell lung cancer

“…Lung cancer has one of the highest fatality rates among malignant tumors in China ( 21 , 22 ). Compared with small cell lung cancer, NSCLC has a slow onset and growth rate but is generally found to be in an advanced stage at initial diagnosis and, therefore, very difficult to control and treat ( 23 - 25 ).…”

Perceptions, Attitudes, Beliefs, and Practices Toward Traditional Chinese Medicine Therapies for Herpes Zoster: A Cross-Sectional Study of Healthcare Professionals

“… 22 As opposed to offsetting the use of WM, TCM provided a complementary role while treating the patients. 23 In China, there were approximately 910 million visits to TCM medical and health service units across the country and 26 million in-patients treated annually. 24 TCM is not only applied in China but also overseas.…”